HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics

More filters

Study design
Intervention type
Study phase
23studies shown
Showing 1-12 of 23
Drug study icon
RecruitingNCT05995782

FB418 or placebo: safety of single and repeated doses in healthy adults and older adults

About this titleRead the official source — NCT05995782
Official study title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD and MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral FB418 in Healthy Adult Subjects and Healthy Elderly Subjects

Recruiting in South Korea
SchizophreniaMedication studyAges 19+
Countries
South Korea
Sponsor
1ST Biotherapeutics, Inc.
Behavioral study icon
RecruitingNCT07242625

The NDTx-02 app and executive function in children with ADHD or autism

About this titleRead the official source — NCT07242625
Official study title

A Multi-center, Prospective, Compared, Randomized, Evaluator-blinded, Pilot Study to Evaluate the Effectiveness of Digital Therapeutics 'NDTx-02' on Executive Function in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) or Autism Spectrum Disorder (ASD)

Recruiting in South Korea
ADHDDevice studyAges 5–12
Countries
South Korea
Sponsor
Neudive Inc.
Drug study icon
RecruitingNCT07219953

Brenipatide for alcohol use and drinking risk

About this title

A Study of Brenipatide in Participants With Alcohol Use Disorder

Read the official source — NCT07219953
Official study title

A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Alcohol Use Disorder (RENEW-ALC-2)

Recruiting in South Korea
AddictionMedication studyAges 18–75
Countries
South Korea, United States, United Kingdom, + 5 others
Sponsor
Eli Lilly and Company
Drug study icon
RecruitingNCT07219966

Brenipatide for moderate to severe alcohol use

About this title

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

Read the official source — NCT07219966
Official study title

A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)

Recruiting in South Korea
AddictionMedication studyAges 18–75
Countries
South Korea, United States, United Kingdom, + 5 others
Sponsor
Eli Lilly and Company
Other study type icon
RecruitingNCT07263191

Olanzapine and weight education for people with bipolarity

About this title

A Study of Olanzapine in Participants With Bipolar Disorder.

Read the official source — NCT07263191
What is this study about?

Researchers observe how olanzapine is used in routine care for people with bipolarity. They examine treatment patterns and whether education about weight gain is associated with less weight gain; the study does not assign or change treatment.

Recruiting in South Korea
BipolarityObservational studyAges 19+
Countries
South Korea
Sponsor
Boryung Pharmaceutical Co., Ltd
Drug study icon
RecruitingNCT06887192

ML-007C-MA for psychosis associated with Alzheimer’s disease

About this titleRead the official source — NCT06887192
Official study title

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis

Recruiting in South Korea
SchizophreniaMedication studyAges 55–90
Countries
South Korea, United States, France, + 12 others
Sponsor
MapLight Therapeutics
Drug study icon
RecruitingNCT06585787

KarXT or placebo for psychosis in Alzheimer’s disease

About this titleRead the official source — NCT06585787
Official study title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease

Recruiting in South Korea
SchizophreniaMedication studyAges 55–90
Countries
South Korea, United States, France, + 21 others
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Drug study icon
RecruitingNCT07196501

Osavampator or placebo to maintain depression treatment response

About this titleRead the official source — NCT07196501
Official study title

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

Recruiting in South Korea
DepressionMedication studyAges 18+
Countries
South Korea, United States, Australia, + 8 others
Sponsor
Neurocrine Biosciences (Biotech company)
Drug study icon
RecruitingNCT06159673

ACP-204 or placebo for psychosis linked to Alzheimer’s disease

About this titleRead the official source — NCT06159673
Official study title

A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer's Disease Psychosis

Recruiting in South Korea
SchizophreniaMedication studyAges 55–95
Countries
South Korea, United States, France, + 9 others
Sponsor
ACADIA Pharmaceuticals Inc.

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.